AMBBY logo

Ambu A/S (AMBBY)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Ambu A/S (AMBBY) with AI Score 47/100 (Weak). Ambu A/S is a Danish medical device company specializing in single-use endoscopes and other medical equipment. The company operates globally, providing solutions for visualization, anesthesia, and patient monitoring. Market cap: 0, Sector: Healthcare.

Last analyzed: Mar 16, 2026
Ambu A/S is a Danish medical device company specializing in single-use endoscopes and other medical equipment. The company operates globally, providing solutions for visualization, anesthesia, and patient monitoring.
47/100 AI Score

Ambu A/S (AMBBY) Healthcare & Pipeline Overview

CEOBritt Meelby Jensen
Employees5000
HeadquartersBallerup, DK
IPO Year2021

Ambu A/S, a Danish medical device innovator, focuses on single-use endoscopes and related medical solutions. With a global presence, the company addresses visualization, anesthesia, and patient monitoring needs, differentiating itself through its emphasis on disposable devices within the competitive medical device landscape, marked by companies like AMFPF and BUHPF.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 16, 2026

Investment Thesis

Ambu A/S presents a compelling investment case based on its innovative single-use endoscope technology and expanding market presence. With a market capitalization of $2.96 billion and a P/E ratio of 35.40, the company demonstrates solid financial standing. Key value drivers include the increasing adoption of single-use endoscopes to reduce infection risks and improve workflow efficiency in hospitals. Growth catalysts include expanding product lines and geographic reach, particularly in North America and Asia. However, potential risks include competition from established medical device manufacturers and the need for continuous innovation to maintain market leadership. The company's gross margin of 55.9% and profit margin of 8.9% indicate healthy profitability, while its beta of 1.40 suggests higher volatility compared to the market.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $2.96 billion reflects investor confidence in Ambu's growth potential.
  • P/E ratio of 35.40 indicates a premium valuation, reflecting expectations of future earnings growth.
  • Gross margin of 55.9% demonstrates efficient cost management and strong pricing power.
  • Profit margin of 8.9% showcases the company's ability to convert revenue into profit.
  • Dividend yield of 0.57% provides a modest income stream for investors.

Competitors & Peers

Strengths

  • Innovative single-use endoscope technology
  • Strong brand reputation
  • Established distribution network
  • Focus on infection control

Weaknesses

  • Reliance on single-use products
  • Limited presence in some geographic markets
  • Higher cost compared to reusable endoscopes
  • Dependence on regulatory approvals

Catalysts

  • Ongoing: Increasing adoption of single-use endoscopes in hospitals and clinics due to infection control concerns.
  • Upcoming: Potential new product launches in the single-use endoscopy market within the next 12-18 months.
  • Ongoing: Expansion into new geographic markets, particularly in Asia-Pacific, driving revenue growth.
  • Upcoming: Strategic partnerships or acquisitions to expand product portfolio and market access by 2027.
  • Ongoing: Growing awareness of the benefits of single-use devices in terms of cost-effectiveness and workflow efficiency.

Risks

  • Ongoing: Competition from established medical device manufacturers with greater resources and market share.
  • Potential: Pricing pressure from healthcare providers and insurance companies may impact profitability.
  • Potential: Technological obsolescence could render existing products less competitive.
  • Potential: Changes in regulatory requirements could increase compliance costs and delay product approvals.
  • Ongoing: Currency fluctuations may negatively impact revenue and earnings.

Growth Opportunities

  • Expansion in the U.S. Market: Ambu has a significant opportunity to expand its presence in the U.S. market, driven by the increasing adoption of single-use endoscopes in hospitals and ambulatory surgery centers. The U.S. medical device market is the largest in the world, with a growing emphasis on infection control and cost-effectiveness. Ambu's single-use endoscopes offer a compelling value proposition in this context. The company can leverage its existing sales infrastructure and distribution network to penetrate new accounts and expand its market share. This expansion is expected to contribute significantly to revenue growth over the next 3-5 years.
  • Product Innovation and Expansion: Ambu can drive growth through continuous product innovation and expansion of its single-use endoscope portfolio. The company has a strong track record of developing and launching new products that address unmet clinical needs. By investing in R&D and collaborating with healthcare professionals, Ambu can develop innovative solutions for various medical specialties, including pulmonology, urology, and gastroenterology. This product expansion will enable Ambu to capture a larger share of the endoscopy market and drive revenue growth. New product launches are anticipated within the next 2-3 years.
  • Geographic Expansion in Asia-Pacific: The Asia-Pacific region represents a significant growth opportunity for Ambu, driven by the increasing healthcare expenditure and rising demand for advanced medical technologies. Countries such as China, India, and Japan are experiencing rapid economic growth and are investing heavily in healthcare infrastructure. Ambu can leverage its existing presence in the region and expand its sales and marketing efforts to capture a larger share of the market. This geographic expansion is expected to contribute significantly to revenue growth over the next 3-5 years.
  • Strategic Partnerships and Acquisitions: Ambu can accelerate its growth through strategic partnerships and acquisitions. The company can partner with other medical device manufacturers, distributors, and healthcare providers to expand its product portfolio, geographic reach, and market access. Acquisitions can also provide Ambu with access to new technologies, markets, and customer segments. These strategic initiatives can enhance Ambu's competitive position and drive long-term growth. Potential partnerships and acquisitions are being evaluated on an ongoing basis.
  • Increased Adoption of Single-Use Endoscopes: The increasing awareness of infection control and the need for efficient workflow in hospitals are driving the adoption of single-use endoscopes. Ambu is well-positioned to benefit from this trend, as its single-use endoscopes offer a compelling value proposition in terms of safety, convenience, and cost-effectiveness. The company can leverage its marketing and sales efforts to educate healthcare professionals about the benefits of single-use endoscopes and drive adoption. This increased adoption is expected to contribute significantly to revenue growth over the next 3-5 years.

Opportunities

  • Expansion in the U.S. market
  • Product innovation and expansion
  • Geographic expansion in Asia-Pacific
  • Strategic partnerships and acquisitions

Threats

  • Competition from established medical device manufacturers
  • Pricing pressure from healthcare providers
  • Technological obsolescence
  • Changes in regulatory requirements

Competitive Advantages

  • Proprietary single-use endoscope technology.
  • Strong brand reputation for innovation and quality.
  • Established distribution network and customer relationships.
  • Focus on infection control and workflow efficiency.

About AMBBY

Founded in 1937 and headquartered in Ballerup, Denmark, Ambu A/S has evolved into a key player in the medical device industry. Initially focused on developing and marketing resuscitation equipment, Ambu gained recognition for inventing the first self-inflating resuscitator bag. Over the decades, the company expanded its product portfolio to include a wide array of medical devices, with a strategic emphasis on single-use endoscopes. These endoscopes are used in various medical procedures, including bronchoscopy, cystoscopy, and rhinolaryngoscopy. Ambu's product offerings also encompass visualization, anesthesia, and patient monitoring and diagnostics. The company serves hospitals, clinics, and rescue services worldwide. Ambu's global reach extends across North America, Europe, and Asia-Pacific, with a direct sales force and a network of distributors. The company's focus on innovation and single-use devices positions it uniquely within the competitive medical device market, challenging traditional reusable equipment models.

What They Do

  • Develops single-use endoscopes for various medical procedures.
  • Produces visualization devices for bronchoscopy, cystoscopy, and rhinolaryngoscopy.
  • Offers anesthesia products, including face masks and resuscitators.
  • Provides patient monitoring and diagnostic equipment.
  • Manufactures neurology products, such as EEG and EMG electrodes.
  • Creates cardiology products, including ECG electrodes.
  • Supplies airway management and anaesthesia products.

Business Model

  • Develops, manufactures, and sells medical devices.
  • Focuses on single-use endoscopes and related products.
  • Distributes products through a direct sales force and a network of distributors.
  • Generates revenue from product sales to hospitals, clinics, and rescue services.

Industry Context

Ambu A/S operates within the global medical device industry, a market characterized by continuous innovation and increasing demand for advanced healthcare solutions. The industry is driven by factors such as an aging population, rising healthcare expenditure, and technological advancements. The single-use endoscope market, in particular, is experiencing rapid growth due to concerns about infection control and the need for efficient workflow in hospitals. Ambu competes with established medical device manufacturers such as AMFPF and BUHPF, as well as smaller players specializing in endoscopy and related products. The company's focus on single-use devices positions it favorably in this evolving landscape.

Key Customers

  • Hospitals
  • Clinics
  • Rescue services
  • Ambulatory surgery centers
AI Confidence: 82% Updated: Mar 16, 2026

Financials

Chart & Info

Ambu A/S (AMBBY) stock price: Price data unavailable

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMBBY.

Price Targets

Wall Street price target analysis for AMBBY.

MoonshotScore

47/100

What does this score mean?

The MoonshotScore rates AMBBY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Britt Meelby Jensen

CEO

Britt Meelby Jensen serves as the CEO of Ambu A/S, leading a global workforce of 5000 employees. Her career spans various leadership roles within the healthcare and pharmaceutical industries. Prior to joining Ambu, she held executive positions at companies such as Novo Nordisk and ALK-Abelló, where she focused on commercial strategy, market access, and business development. Jensen holds a Master's degree in Economics and Business Administration from Copenhagen Business School.

Track Record: Since assuming the role of CEO, Britt Meelby Jensen has focused on driving growth through innovation, geographic expansion, and strategic partnerships. Under her leadership, Ambu has strengthened its position in the single-use endoscope market and expanded its product portfolio. She has also overseen the company's expansion into new markets, particularly in North America and Asia. Key milestones include the launch of several new single-use endoscope products and the acquisition of a complementary medical device company.

Ambu A/S ADR Information Unsponsored

An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are traded on U.S. stock exchanges. AMBBY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without the same stringent SEC reporting requirements as listed companies. This allows U.S. investors to invest in Ambu A/S without directly dealing with foreign stock exchanges.

  • Home Market Ticker: Nasdaq Copenhagen, Denmark
  • ADR Level: 1
  • ADR Ratio: 1:1
  • Home Market Ticker: AMBB
Currency Risk: Investing in AMBBY exposes U.S. investors to currency risk, as the ADR's value is affected by fluctuations in the exchange rate between the U.S. dollar and the Danish Krone. If the Krone weakens against the dollar, the value of the ADR may decrease, even if the underlying stock price in Denmark remains constant.
Tax Implications: U.S. investors in AMBBY may be subject to foreign dividend withholding taxes imposed by the Danish government. The standard withholding tax rate on dividends paid to foreign investors is 27%. However, the U.S. has a tax treaty with Denmark that may reduce the withholding tax rate to 15% for eligible U.S. investors. Investors should consult with a tax advisor to determine their specific tax obligations.
Trading Hours: The Nasdaq Copenhagen stock exchange operates from 09:00 to 17:00 Central European Time (CET). This translates to 03:00 to 11:00 Eastern Time (ET). As AMBBY trades over-the-counter (OTC) in the U.S., its trading hours may not fully align with the Copenhagen exchange. U.S. investors should be aware of the time difference and potential liquidity constraints during off-peak hours.

AMBBY OTC Market Information

The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for less transparency, lower liquidity, and greater price volatility compared to exchange-listed securities. This tier is distinct from the higher OTCQX and OTCQB tiers, which have more stringent listing standards.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: As an OTC Other stock, AMBBY likely experiences lower trading volume and wider bid-ask spreads compared to exchange-listed stocks. This can make it more difficult to buy or sell shares at desired prices, potentially leading to higher transaction costs and increased price volatility. Investors should be prepared for potential liquidity constraints when trading AMBBY.
OTC Risk Factors:
  • Limited financial disclosure
  • Lower trading volume and liquidity
  • Wider bid-ask spreads
  • Greater price volatility
  • Potential for fraud or manipulation
Due Diligence Checklist:
  • Verify the company's registration and regulatory filings.
  • Review the company's financial statements, if available.
  • Assess the company's management team and track record.
  • Research the company's industry and competitive landscape.
  • Evaluate the company's business model and growth prospects.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before investing.
Legitimacy Signals:
  • Established operating history (founded in 1937).
  • Global presence and customer base.
  • Focus on innovation and single-use medical devices.
  • Presence of a recognized CEO (Britt Meelby Jensen).
  • ADR listing, even at Level 1, indicates some level of compliance.

What Investors Ask About Ambu A/S (AMBBY)

What does Ambu A/S do?

Ambu A/S is a medical device company specializing in the development, production, and sale of single-use endoscopes and other medical equipment. The company provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. Its primary focus is on single-use endoscopes, which are used in various medical procedures, including bronchoscopy, cystoscopy, and rhinolaryngoscopy. Ambu's products are sold to hospitals, clinics, and rescue services worldwide.

What do analysts say about AMBBY stock?

Analyst coverage of AMBBY is limited due to its OTC listing. However, the company's focus on single-use endoscopes and its growth potential in the medical device market are generally viewed positively. Key valuation metrics include the company's P/E ratio of 35.40 and its market capitalization of $2.96 billion. Growth considerations include the increasing adoption of single-use devices and the company's expansion into new markets. Investors should conduct their own research and consider their individual risk tolerance before investing in AMBBY.

What are the main risks for AMBBY?

The main risks for AMBBY include competition from established medical device manufacturers, pricing pressure from healthcare providers, technological obsolescence, changes in regulatory requirements, and currency fluctuations. As an OTC-listed stock, AMBBY also faces risks related to limited financial disclosure, lower trading volume, and greater price volatility. Investors should carefully consider these risks before investing in AMBBY.

How does Ambu A/S manage patent expiration risks?

As a medical device company, Ambu A/S faces the risk of patent expirations on its key products. To mitigate this risk, Ambu invests in continuous research and development to develop new and innovative products. The company also employs lifecycle management strategies to extend the commercial life of its existing products, such as developing new formulations or indications. Ambu also actively monitors the competitive landscape and prepares for the entry of biosimilar or generic products upon patent expiration.

What revenue streams does Ambu A/S have in healthcare?

Ambu A/S generates revenue from the sale of its medical devices to hospitals, clinics, and rescue services worldwide. The company's revenue streams are diversified across various product lines, including single-use endoscopes, anesthesia products, and patient monitoring equipment. Geographically, Ambu generates revenue from North America, Europe, and Asia-Pacific. The company's revenue is also diversified across various medical specialties, including pulmonology, urology, and gastroenterology. The single-use endoscope segment is a significant contributor to Ambu's overall revenue.

What are the key factors to evaluate for AMBBY?

Ambu A/S (AMBBY) currently holds an AI score of 47/100, indicating low score. Key strength: Innovative single-use endoscope technology. Primary risk to monitor: Ongoing: Competition from established medical device manufacturers with greater resources and market share.. This is not financial advice.

How frequently does AMBBY data refresh on this page?

AMBBY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven AMBBY's recent stock price performance?

Recent price movement in Ambu A/S (AMBBY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative single-use endoscope technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • OTC data may be less reliable than exchange-listed data.
  • Analyst coverage may be limited due to OTC listing.
Data Sources

Popular Stocks